EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Absolute monocyte counts could predict disease activity and secondary loss of response of patients with Crohn’s disease treated with anti-TNF-α drug

Jia Hu, Yin Huang, Ruonan Jia, Xuehong Wang, Yongjun Wang iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0301797 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Jia Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Biological Products, Crohn Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Assessing Crohn’s disease (CD) activity is critical for monitoring disease progression. In CD, monocytes could release TNF-α. Thus, it is extremely important to study its role in the disease activity and loss of response to anti-TNF-α biologics.

Methods

In this study, we collected CD patients treated with biologics from January 2017 to May 2022. Indicators associated with disease activity were evaluated by Spearman correlation analysis and Mann-Whitney U test. Specifically, logistic analyses were used to explore the predictors of primary nonresponse (PNR) and secondary loss of response (SLOR) within 1 year of anti-TNF-α agents. In addition, a nomogram was developed for therapeutic effect prediction.

Results

283 patients with CD were identified. Disease activity group, defined as CDAI equal to or greater than 150, had significant elevated absolute monocyte counts than disease remission group based on CDAI score (p = 0.019, Z = -2.354). Logistic analyses showed that absolute monocyte counts could be an independent predictor of 1-year SLOR of anti-TNF-α agents in CD patients (p = 0.013). A nomogram established based on gender, absolute monocyte counts, and hemoglobin could predict SLOR within 1 year of anti-TNF-α agents reliably.

Conclusion

The results of this study support the utility of absolute monocyte counts detecting disease activity and anti-TNF-α therapy effect in patients with CD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsCrohn DiseaseHumansMonocytesTumor Necrosis Factor InhibitorsTumor Necrosis Factor-alpha

Substanzen

Biological ProductsTumor Necrosis Factor InhibitorsTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Research Center of Digestive Disease, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

ORCID-Profile: Yongjun Wang

Zitieren

APA

Hu, J., Huang, Y., Jia, R., Wang, X., & Wang, Y. (2024). Absolute monocyte counts could predict disease activity and secondary loss of response of patients with Crohn’s disease treated with anti-TNF-α drug. PLOS ONE. https://doi.org/10.1371/journal.pone.0301797

Vancouver

Hu J, Huang Y, Jia R, Wang X, Wang Y. Absolute monocyte counts could predict disease activity and secondary loss of response of patients with Crohn’s disease treated with anti-TNF-α drug. PLOS ONE. 2024. doi:10.1371/journal.pone.0301797

BibTeX
@article{Hu2024,
  author = {Hu, Jia and Huang, Yin and Jia, Ruonan and Wang, Xuehong and Wang, Yongjun},
  title = {Absolute monocyte counts could predict disease activity and secondary loss of response of patients with Crohn’s disease treated with anti-TNF-α drug},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0301797}
}
Kostenlos starten →